Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64

Benzinga Newsdesk www.benzinga.com Positive 91.4%

Neg 0% Neu 0% Pos 91.4%

Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.